{
  "id": "58962ed178275d0c4a000006",
  "type": "list",
  "question": "Entresto is composed of which two drugs?",
  "ideal_answer": "Entresto is composed of sacubitril and valsartan. It is newly FDA-approved medication that dually inhibits angiotensin and neprilysin, in the treatment of heart failure.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/27697814",
    "http://www.ncbi.nlm.nih.gov/pubmed/26642078",
    "http://www.ncbi.nlm.nih.gov/pubmed/26976916",
    "http://www.ncbi.nlm.nih.gov/pubmed/27284124",
    "http://www.ncbi.nlm.nih.gov/pubmed/26417173",
    "http://www.ncbi.nlm.nih.gov/pubmed/26992459",
    "http://www.ncbi.nlm.nih.gov/pubmed/26975167",
    "http://www.ncbi.nlm.nih.gov/pubmed/26466333",
    "http://www.ncbi.nlm.nih.gov/pubmed/27378659",
    "http://www.ncbi.nlm.nih.gov/pubmed/27804100",
    "http://www.ncbi.nlm.nih.gov/pubmed/26873495"
  ],
  "snippets": [
    {
      "text": "The PARADIGM-HF study, a large outcome trial in heart failure and reduced ejection fraction (HFrEF), has recently shown improved cardiovascular outcomes with sacubitril/valsartan (Entresto\u00ae, Novartis), still commonly referred to as LCZ696, compared to ACE-inhibitor therapy, possibly leading us to a new era for heart failure (HF) treatment. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26642078",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "This article reviews the background, current knowledge and data supporting the use of sacubitril/valsartan (Entresto(\u00ae) ), the newly FDA-approved medication that dually inhibits angiotensin and neprilysin, in the treatment of heart failure.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26992459",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "\u25bc Sacubitril valsartan (Entresto-Novartis) is a new oral drug licensed for the treatment of symptomatic chronic heart failure in adults with reduced ejection fraction.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27284124",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Rhabdomyolysis After Coadministration of Atorvastatin and Sacubitril/Valsartan (Entresto\u2122) in a 63-Year-Old Woman.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27804100",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "A 63-year-old woman previously stable on a regimen of atorvastatin 40\u00a0mg daily, carvedilol 25\u00a0mg twice daily, digoxin 0.125\u00a0mg daily, furosemide 40\u00a0mg daily, spironolactone 25\u00a0mg daily, rivaroxaban 15\u00a0mg daily, and enalapril 20\u00a0mg twice daily for heart failure developed rhabdomyolysis 26\u00a0days after enalapril was stopped and sacubitril/valsartan (Entresto\u2122) started.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27804100",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Sacubitril/valsartan [LCZ696 (Entresto), Novartis Pharmaceuticals Corp.] is the first in a new class of drugs that combines neprilysin inhibition with angiotensin II receptor antagonism, the combination of which acts to increase endogenous natriuretic peptides while inhibiting the renin-angiotensin-aldosterone system.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26466333",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "In July 2015, the US Food and Drug Administration approved the first of a new class of drugs for the treatment of heart failure: Valsartan/sacubitril (formerly known as LCZ696 and currently marketed by Novartis as Entresto) combines the angiotensin receptor blocker valsartan and the neprilysin inhibitor prodrug sacubitril in a 1:1 ratio in a sodium supramolecular complex.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26976916",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Sacubitril/valsartan (Entresto) for chronic heart failure; brexpiprazole (Rexulti) for major depressive disorder and schizophrenia; and lumacaftor/ivacaftor (Orkambi) for cystic fibrosis involving specific CFTR mutations.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26417173",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Sacubritil\u2217valsartan (Entresto, Novartis, still commonly referred to as LCZ696) is a combination drug described as a new class of dual-acting angiotensin receptor-neprilysin inhibitor (ARNi).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27378659",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The molecular combination of sacubitril and valsartan (Entresto) is a new drug for reducing the risk of cardiovascular death and hospitalization for heart failure in patients with chronic heart failure (NYHA Class II-IV) and reduced ejection fraction.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26975167",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "\u25bc Sacubitril valsartan (Entresto-Novartis) is a new oral drug licensed for the treatment of symptomatic chronic heart failure in adults with reduced ejection fraction.(1) It is described as an angiotensin receptor neprilysin inhibitor and contains the neprilysin inhibitor, sacubitril and the angiotensin II receptor antagonist, valsartan.(1-3) Here, we review the evidence for sacubitril valsartan and consider its place in the management of heart failure.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27284124",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "sacubitril, valsartan"
}